Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

Sorry, invest, I missed the first post. Gold, feel free to fill in anything I couldn't find a reference for.

1. By which means doctors detected the colon cancer in the early stage (stage I and II) currently?

That's a good question. This link here provides far more tests and details than I could off of the top of my head-
http://www.cancer.org/Cancer/ColonandRectumCancer/MoreInformation/ColonandRectumCancerEarlyDetection/colorectal-cancer-early-detection-screening-tests-used

Roughly what's the percentage of the patients who were detected in stage I and II by means other than blood test?

I'm not so sure about this one but I believe the majority are detected using the methods I linked you to above. However, only
about half of the CRC cancers are detected at early stages according to this study-

http://www.cancerview.ca/idc/groups/public/documents/webcontent/rl_crc_snapshot_three_en.pdf

Gold, also this is some proof of the overall stage I and II bias of a sampled population due to the increasing CRC prevalence I mentioned before.

Granted it is for a specific region of our northern neighbor. A national survey may be different.

2. When a person has elevated FDP level in a test with onko-sure, while he is free of cancer, would this level maintain the higher than normal level in subsequent tests? (eg. one or two test monthly after the first)?

Most likely not, if proper procedures are followed. High FDP is almost always indicative of something specifically wrong with your body-some type of degenerative disease. This is obviously not good and must be addressed. FDP levels in a non cancerous individuals will drop after treatment of the disease or diseases. In the case of smoking and benign tumors, FDP levels may remain elevated unless smoking stops or benign tumors are removed.

And when a person has cancer in progression in the early stage, would the FDP level increase with time?

Yes, FDP levels do increase with progression of cancer. This was actually the basis for the original FDA submission. They used 15% increase or decrease to indicate a growth or reduction respectively of cancer in the clinical trial subjects.